Back to Cell Types

NCI-H1568Homo sapiens (Human)Cancer cell line

Also known as: NCIH1568, H-1568, H1568

🤖 AI SummaryBased on 12 publications

Quick Overview

Human lung cancer cell line with known genetic alterations and drug sensitivity profiles.

Detailed Summary

The NCI-H1568 cell line is a human lung cancer cell line derived from a small cell lung cancer (SCLC) tumor. It is characterized by specific genetic alterations, including mutations in the RB1 gene, which is a key tumor suppressor involved in cell cycle regulation. This cell line has been extensively studied for its response to various therapeutic agents, showing sensitivity to certain chemotherapeutic drugs and targeted therapies. Research on NCI-H1568 has contributed to understanding the molecular mechanisms underlying SCLC progression and drug resistance. The cell line is also used in studies investigating the role of RB1 mutations in cancer development and the potential for targeted therapies based on these mutations.

Research Applications

Cancer geneticsDrug sensitivity profilingTumor suppressor gene functionCell cycle regulation

Key Characteristics

RB1 mutationSCLC originDrug sensitivityGenomic instability

Generated on 6/17/2025

Basic Information

Database ID	CVCL_1476
Species	Homo sapiens (Human)
Tissue Source	Lymph node[UBERON:UBERON_0000029]

Donor Information

Age	48
Age Category	Adult
Sex	Female
Race	caucasian

Disease Information

Disease	Lung adenocarcinoma
Lineage	Lung
Subtype	Lung Adenocarcinoma
OncoTree Code	LUAD

DepMap Information

Source Type	ATCC
Source ID	ACH-000869_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	p.His179Arg (c.536A>G)	Unspecified	-	PubMed=35297208
MutationSimple	ATM	p.Gly506Phe (c.1516_1517GG>TT)	Heterozygous	-	Unknown, Unknown, PubMed=27602502

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X

CSF1PO

11

D13S317

11

D16S539

10,12

D18S51

18

D19S433

13,14

D21S11

29

D2S1338

18,20

D3S1358

17

D5S818

9

D7S820

8,9

D8S1179

13,14

FGA

23

Penta D

11

Penta E

12

TH01

7,9

TPOX

8,11

vWA

16,17

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.

Aldige C.R., Wistuba I.I., Minna J.D.

J. Cell. Biochem. 121:3986-3999(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Chemistry-first approach for nomination of personalized treatment in lung cancer.

Posner B.A., Minna J.D., Kim H.S., White M.A.

Cell 173:864-878.e29(2018).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

Phenotypic consequences of somatic mutations in the ataxia-telangiectasia mutated gene in non-small cell lung cancer.

Maughan T.S., Ryan A.J.

Oncotarget 7:60807-60822(2016).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

Comparative proteome analysis across non-small cell lung cancer cell lines.

Daub H.

J. Proteomics 130:1-10(2016).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

Heymach J.V.

Cancer Discov. 2:798-811(2012).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

Zhou X.-M., Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.

Cell 131:1190-1203(2007).

Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.

Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.

Oncogene 19:4632-4639(2000).

NCI-Navy Medical Oncology Branch cell line data base.";

Carney D.N., Minna J.D., Mulshine J.L.

J. Cell. Biochem. Suppl. 24:32-91(1996).

p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.

Gazdar A.F.

Oncogene 7:171-180(1992).

Web Resources